ATE275141T1 - Substituierte imidazolin-derivate - Google Patents
Substituierte imidazolin-derivateInfo
- Publication number
- ATE275141T1 ATE275141T1 AT00966483T AT00966483T ATE275141T1 AT E275141 T1 ATE275141 T1 AT E275141T1 AT 00966483 T AT00966483 T AT 00966483T AT 00966483 T AT00966483 T AT 00966483T AT E275141 T1 ATE275141 T1 AT E275141T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- signifies
- pain
- morphine
- chem
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29123299 | 1999-10-13 | ||
PCT/JP2000/007133 WO2001027104A1 (fr) | 1999-10-13 | 2000-10-13 | Derives d'imidazolidinone a substitution |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275141T1 true ATE275141T1 (de) | 2004-09-15 |
Family
ID=17766196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00966483T ATE275141T1 (de) | 1999-10-13 | 2000-10-13 | Substituierte imidazolin-derivate |
Country Status (8)
Country | Link |
---|---|
US (1) | US6699880B1 (de) |
EP (1) | EP1221443B1 (de) |
AT (1) | ATE275141T1 (de) |
AU (1) | AU766233B2 (de) |
CA (1) | CA2387535A1 (de) |
DE (1) | DE60013464T2 (de) |
ES (1) | ES2223588T3 (de) |
WO (1) | WO2001027104A1 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2470578C (en) | 2001-12-28 | 2010-10-12 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
EP1515722A4 (de) | 2002-06-17 | 2006-06-21 | Merck & Co Inc | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie |
WO2004064835A1 (en) * | 2003-01-17 | 2004-08-05 | Neurosearch A/S | Use of ion channel modulating agents for treating pain |
WO2004069828A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
WO2004071392A2 (en) * | 2003-02-11 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
WO2005009996A1 (en) * | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
MXPA06000700A (es) * | 2003-07-23 | 2006-04-11 | Wyeth Corp | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. |
CA2469512A1 (en) | 2004-06-02 | 2005-12-02 | Jeffrey Harrison | Fish feed apparatus for underwater feeding |
JP5209479B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有するベンゾイミダゾロン類 |
ES2391107T3 (es) | 2005-09-30 | 2012-11-21 | Glaxo Group Limited | Compuestos que tienen actividad en el receptor M1 y sus usos en medicina |
EA016286B1 (ru) | 2005-09-30 | 2012-03-30 | Глэксо Груп Лимитед | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
AU2008231789A1 (en) * | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
GB0706187D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706167D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
CA2689663C (en) | 2007-06-13 | 2016-08-09 | Incyte Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
GB0718415D0 (en) | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR20220015492A (ko) * | 2010-03-10 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
PL2574168T3 (pl) | 2010-05-21 | 2016-10-31 | Preparaty inhibitora kinazy janusowej do stosowania miejscowego | |
WO2011163594A2 (en) * | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
EP2721028B1 (de) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinylphenyl-, pyridyl- oder pyrazinylcarboxamidderivate als jak-inhibitoren |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013072705A1 (en) | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
JP2015083543A (ja) * | 2012-02-14 | 2015-04-30 | 大日本住友製薬株式会社 | 新規縮環ピロリジン誘導体 |
TW201348231A (zh) * | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
PE20200175A1 (es) | 2012-11-15 | 2020-01-24 | Incyte Holdings Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
CN103030580A (zh) * | 2012-12-13 | 2013-04-10 | 山东铂源药业有限公司 | 一种拉帕替尼中间体的制备方法 |
WO2014122474A1 (en) * | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
UA120162C2 (uk) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
EP3394061B1 (de) | 2015-12-23 | 2020-03-11 | Merck Sharp & Dohme Corp. | Allosterische 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-on-modulatoren des m4-muskarinischen acetylcholinrezeptors |
WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU701127B2 (en) * | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
GB9603457D0 (de) * | 1996-02-19 | 1996-04-17 | Merck & Co Inc | |
US5756508A (en) * | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
PL342046A1 (en) * | 1998-01-19 | 2001-05-21 | Pfizer | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as agonists of orl1 receptor |
-
2000
- 2000-10-13 WO PCT/JP2000/007133 patent/WO2001027104A1/ja active IP Right Grant
- 2000-10-13 EP EP00966483A patent/EP1221443B1/de not_active Expired - Lifetime
- 2000-10-13 AU AU76865/00A patent/AU766233B2/en not_active Ceased
- 2000-10-13 DE DE60013464T patent/DE60013464T2/de not_active Expired - Fee Related
- 2000-10-13 AT AT00966483T patent/ATE275141T1/de not_active IP Right Cessation
- 2000-10-13 CA CA002387535A patent/CA2387535A1/en not_active Abandoned
- 2000-10-13 US US10/110,638 patent/US6699880B1/en not_active Expired - Fee Related
- 2000-10-13 ES ES00966483T patent/ES2223588T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU766233B2 (en) | 2003-10-09 |
EP1221443B1 (de) | 2004-09-01 |
ES2223588T3 (es) | 2005-03-01 |
DE60013464T2 (de) | 2005-09-15 |
CA2387535A1 (en) | 2001-04-19 |
EP1221443A4 (de) | 2002-11-04 |
US6699880B1 (en) | 2004-03-02 |
DE60013464D1 (de) | 2004-10-07 |
AU7686500A (en) | 2001-04-23 |
EP1221443A1 (de) | 2002-07-10 |
WO2001027104A1 (fr) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE275141T1 (de) | Substituierte imidazolin-derivate | |
FI7843U1 (fi) | Oksikodonihydrokloridikoostumus | |
DK1178973T3 (da) | Pyrazinyl-piperazin-forbindelser, deres anvendelse og fremstilling | |
DK1285651T3 (da) | Melanin-koncentrerende hormon-antagonister | |
MY140039A (en) | Pyrido-(2,1-a)-isoquinoline derivatives as dpp-iv inhibitors | |
EP1813606A4 (de) | Amidverbindung | |
BR9801020A (pt) | Derivados de azaindol-etilamina como agentes de ligação do receptor de acetilcolina nicotìnico. | |
ATE339409T1 (de) | Trizyklische verbindungen | |
ATE556712T1 (de) | A2a antagonisten zur behandlung von motorischen störungen | |
DE60325973D1 (de) | Spirozyklische piperidine als mch1-antagonisten und ihre verwendungen | |
PT1106614E (pt) | Compostos de 1,4-dihidropiridina substituidos com heteroarilos de 5 membros como antagonistas de bradiquinina | |
ATE347552T1 (de) | Cyclohexylaminderivate und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
ATE302184T1 (de) | Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors | |
BR0002514A (pt) | Derivados de 4-arilpiperidina para o tratamento de prurido | |
ATE278678T1 (de) | Substituierte 1-aza-2-imino-heterocyclen und ihre verwendung als aktivatoren der nikotinergen acetylcholinrezeptoren | |
WO2002080918A1 (fr) | Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire | |
SE9901884D0 (sv) | Novel compounds their use and preparation | |
DE60008396D1 (de) | Amidderivate | |
TH83468B (th) | ยาต้านฤทธิ์ของตัวรับ crf และวิธีการที่เกี่ยวข้องกับเรื่องนี้ | |
TW200513463A (en) | Agents for treatment or prevention of frequent urination and urinary incontinence and morphinan derivatives having a nitrogen-containing cyclic substituent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |